- Home
- EQX vs VERA Comparison
EQX vs VERA Comparison
Compare EQX & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQX
- VERA
- Stock Information
- Founded
- EQX 2007
- VERA 2016
- Country
- EQX Canada
- VERA United States
- Employees
- EQX N/A
- VERA N/A
- Industry
- EQX Precious Metals
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- EQX Basic Materials
- VERA Health Care
- Exchange
- EQX Nasdaq
- VERA Nasdaq
- Market Cap
- EQX 3.2B
- VERA 2.0B
- IPO Year
- EQX N/A
- VERA 2021
- Fundamental
- Price
- EQX $6.15
- VERA $23.20
- Analyst Decision
- EQX
- VERA Buy
- Analyst Count
- EQX 0
- VERA 8
- Target Price
- EQX N/A
- VERA $64.63
- AVG Volume (30 Days)
- EQX 15.7M
- VERA 1.3M
- Earning Date
- EQX 08-13-2025
- VERA 08-07-2025
- Dividend Yield
- EQX N/A
- VERA N/A
- EPS Growth
- EQX N/A
- VERA N/A
- EPS
- EQX 0.64
- VERA N/A
- Revenue
- EQX $1,696,526,000.00
- VERA N/A
- Revenue This Year
- EQX $40.61
- VERA N/A
- Revenue Next Year
- EQX $14.56
- VERA N/A
- P/E Ratio
- EQX $9.66
- VERA N/A
- Revenue Growth
- EQX 54.88
- VERA N/A
- 52 Week Low
- EQX $4.48
- VERA $18.53
- 52 Week High
- EQX $7.45
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- EQX 55.26
- VERA 49.75
- Support Level
- EQX $5.70
- VERA $22.57
- Resistance Level
- EQX $6.12
- VERA $24.58
- Average True Range (ATR)
- EQX 0.18
- VERA 1.13
- MACD
- EQX 0.07
- VERA 0.06
- Stochastic Oscillator
- EQX 91.67
- VERA 38.05
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.